Serum suPAR associated with disease severity and mortality in elderly patients with community-acquired pneumonia

References

• Faverio P, Aliberti S, Bellelli G, et al. The management of community-acquired pneumonia in the elderly. Eur J Intern Med. 2014;25(4):312–319.
   PubMed Web of Science ®Google Scholar
• Fung HB, Monteagudo MO. Community-acquired pneumonia in the elderly. Am J Geriatr Pharmacother. 2010;8(1):47–62.
   PubMedGoogle Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–250.
   PubMed Web of Science ®Google Scholar
• Luo Q, Pu N, Zheng Y, et al. Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study. Crit Care. 2018;22(1):15.
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Williams S, Bowler SD. Australasian respiratory and emergency physicians do not use the pneumonia severity index in community-acquired pneumonia. Respirology. 2013;18(2):291–296.
   PubMed Web of Science ®Google Scholar
• Kolditz M, Ewig S, Klapdor B, et al. Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax. 2015;70(6):551–558.
   PubMed Web of Science ®Google Scholar
• Fernandez JF, Sibila O, Restrepo MI. Predicting ICU admission in community-acquired pneumonia: clinical scores and biomarkers. Expert Rev Clin Pharmacol. 2012;5(4):445–458.
   PubMed Web of Science ®Google Scholar
• Manetti M, Rosa I, Milia AF, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis. 2014;73(9):1700–1709.
   PubMed Web of Science ®Google Scholar
• Genua M, D'Alessio S, Cibella J, et al. The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. Gut. 2015;64(4):589–600.
   PubMed Web of Science ®Google Scholar
• Mazzieri R, Pietrogrande G, Gerasi L, et al. Urokinase receptor promotes skin tumor formation by preventing epithelial cell activation of Notch1. Cancer Res. 2015;75(22):4895–4909.
   PubMed Web of Science ®Google Scholar
• Geboers D, Beer FMD, Boer TD, et al. Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients. Intensive Care Med. 2015;41(7):1281–1290.
   PubMed Web of Science ®Google Scholar
• Khater WS, Salah-Eldeen NN, Khater MS, et al. Role of suPAR and lactic acid in diagnosing sepsis and predicting mortality in elderly patients. Eur J Microbiol Immunol (Bp). 2016;6(3):178–185.
   PubMedGoogle Scholar
• Rasmussen LJH, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33(11):769–775.
   PubMed Web of Science ®Google Scholar
• Capelastegui A, España PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. 2006;27(1):151–157.
   PubMed Web of Science ®Google Scholar
• Spindler C, Ortqvist A. Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. Eur Respir J. 2006;28(4):816–823.
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730–1754.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007;44(Suppl. 2):S27–S72.
   PubMed Web of Science ®Google Scholar
• Maria T, Betina M, Jesper EO. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157–172.
   PubMed Web of Science ®Google Scholar
• Garcia-Monco JC, Coleman JL, Benach JL. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol. 2002;129(1–2):216–223.
   PubMed Web of Science ®Google Scholar
• Rudolf F, Wagner AJ, Back FM, et al. Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR. Int J Tuberc Lung Dis. 2017;21(1):67–72.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Raggam RB, Wagner J, et al. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome. Clin Biochem. 2013;46(3):225–229.
   PubMed Web of Science ®Google Scholar
• Mölkänen T, Ruotsalainen E, Thorball CW, et al. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2011;30(11):1417–1424.
   PubMed Web of Science ®Google Scholar
• Huttunen R, Syrjänen J, Vuento R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med. 2011;270(1):32–40.
   PubMed Web of Science ®Google Scholar
• Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15(1):R63.
   PubMed Web of Science ®Google Scholar
• Wittenhagen P, Kronborg G, Weis N, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect. 2004;10(5):409–415.
   PubMed Web of Science ®Google Scholar
• Møller HJ, Moestrup SK, Weis N, et al. Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med. 2006;34:2561–2566.
   PubMed Web of Science ®Google Scholar
• Savva A, Raftogiannis M, Baziaka F, et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect. 2011;63(5):344–350.
   PubMed Web of Science ®Google Scholar
• Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11(2):R38.
   PubMed Web of Science ®Google Scholar
• Donadello K, Scolletta S, Covajes C, et al. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10:2.
   PubMed Web of Science ®Google Scholar
• Donadello K, Covajes C, Scolletta S, et al. Clinical value of suPAR, a new biomarker. Intensive Care Med. 2011;37:S199.
   Web of Science ®Google Scholar
• Donadello K, Scolletta S, Taccone FS, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care. 2014;29(1):144–149.
   PubMed Web of Science ®Google Scholar
• Uusitalo-Seppala R, Huttunen R, Tarkka M, et al. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med. 2012;272(3):247–256.
   PubMed Web of Science ®Google Scholar
• Botha S, Fourie CM, Schutte R, et al. Associations of suPAR with lifestyle and cardiometabolic risk factors. Eur J Clin Invest. 2014;44(7):619–626.
   PubMed Web of Science ®Google Scholar